Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

    ... prognosis. The mainstay of treatment includes cytoxic chemotherapy and supportive care . Over the last decade, promising ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. The epidemiology of myelodysplastic syndromes.

    ... include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... therapies include cytarabine-based remission induction chemotherapy and hematopoietic stem cell transplantation. Transplantation ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Impact on survival of different treatments for myelodysplastic syndromes (MDS).

    ... low-dose Ara-C, antithymocyte globulin (ATG), induction chemotherapy , or allogeneic stem cell transplantation (allo-SCT). For all ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... syndromes who are not candidates for high-dose chemotherapy . Considering the mechanism of action of the agent, it is ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of ...

    Research Article last updated 02/04/2014 - 1:37pm.

  8. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.

    ... yrs were more likely to receive active therapies (i.e., chemotherapy , immunomodulatory therapy, or epigenetic therapy) than ...

    Research Article last updated 10/22/2013 - 2:33pm.

  9. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... (CCR), which included low-dose ara-C, BSC, or intensive chemotherapy . In both studies, azacitidine dose was 75 mg/m(2)/d SC for 7 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of ...

    Research Article last updated 07/31/2012 - 2:02pm.